Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.51 |
| ▸ | CCR4 | P51679 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
| ▸ | RHEB | Q15382 | 3/20 | 0.36 |
| ▸ | ESRRA | P11474 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MPO | P05164 | 2/20 | 0.34 |
| ▸ | BCDIN3D | Q7Z5W3 | 2/20 | 0.34 |
| ▸ | BPTF | Q12830 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.32 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3484323 | 0.80 | RHEB (0.54) | EGFRERBB2RHEBESRRAMEN1 | |
| SCHEMBL3483787 | 0.74 | MEN1 (0.39) | EGFRERBB2MEN1KMT2A | |
| SCHEMBL3484335 | 0.73 | EGFR (0.80) | EGFRERBB2 | |
| SCHEMBL3484572 | 0.72 | ESRRA (0.56) | SCN9ARHEBESRRA | |
| SCHEMBL1964539 | 0.72 | CYP3A4 (0.56) | MEN1KMT2A | |
| SCHEMBL3403550 | 0.71 | EGFR (0.48) | EGFRERBB2RHEBESRRA | |
| SCHEMBL3484118 | 0.71 | NOS1 (0.50) | EGFRERBB2RHEBMEN1KMT2A | |
| SCHEMBL3484180 | 0.71 | BRD4 (0.39) | SCN9ARHEBESRRAMEN1KMT2A | |
| SCHEMBL3484744 | 0.71 | EPHB3 (0.39) | EGFRERBB2MEN1KMT2A | |
| SCHEMBL3484540 | 0.71 | HTR2C (0.49) | EGFRERBB2RHEB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | EGFR 13/4885ERBB2 1/4885CCR4 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.